CURRAX PHARMACEUTICALS
February 25, 2025
Press Releases
CURRAX PHARMACEUTICALS
January 10, 2025
Currax Announces Outstanding 2024 Financial and Operational Performance
See moreCONTRAVE®
January 2, 2025
Currax Introduces First CONTRAVE® TV Ad and “Cravings Don’t Own Me” Campaign, Highlighting Food Cravings Management and Weight Loss
See moreCURRAX PHARMACEUTICALS
September 24, 2024
Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss
See moreCONTRAVE®/MYSIMBA®
August 27, 2024
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
See moreCONTRAVE®/MYSIMBA®
July 24, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
See moreCURRAX PHARMACEUTICALS
January 25, 2024
Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial
See moreCONTRAVE®/MYSIMBA®
October 19, 2023
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® demonstrates no increased risk in major adverse cardiac events in a large, long-term real-world evidence study
See moreCONTRAVE®
March 6, 2023